Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Sep;81(12):838-848.
doi: 10.1002/pros.24180. Epub 2021 Jun 14.

Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

Caroline E Nunes-Xavier  1   2 , Wanja Kildal  3 , Andreas Kleppe  3   4 , Håvard E Danielsen  3   4   5 , Håkon Waehre  3 , Roberto Llarena  6 , Gunhild M Maelandsmo  1 , Øystein Fodstad  1   7 , Rafael Pulido  2   8 , José I López  2   9
Affiliations
Multicenter Study

Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

Caroline E Nunes-Xavier et al. Prostate. 2021 Sep.

Abstract

Background: Novel immune checkpoint-based immunotherapies may benefit specific groups of prostate cancer patients who are resistant to other treatments.

Methods: We analyzed by immunohistochemistry the expression of B7-H3, PD-L1/B7-H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway.

Results: B7-H3 expression correlated positively with AR expression and was associated with biochemical recurrence in the Spanish cohort, but PD-L1 expression correlated with neither of them. Findings for B7-H3 were validated in the Norwegian cohort, where B7-H3 expression correlated positively with Gleason grade, surgical margins, seminal vesicle invasion, and CAPRA-S risk group, and was associated with clinical recurrence. High B7-H3 expression in the Norwegian cohort was also consistent with positive AR expression.

Conclusion: These results suggest distinct clinical relevance of the two immune checkpoint proteins PD-L1 and B7-H3 in prostate cancer. Our findings highlight B7-H3 as an actionable novel immune checkpoint protein in prostate cancer.

Keywords: B7-H3/CD276; PD-L1/CD274; androgen receptor (AR); immune checkpoint protein; prostate cancer.

PubMed Disclaimer

References

REFERENCES

    1. American Cancer Society. Facts & Figures 2020. American Cancer Society. Atlanta G. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
    1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.
    1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2(5):389-396.
    1. Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307-318.

Publication types

MeSH terms